Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 19/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500438 | 0.97 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL30255208 | 0.97 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL20500381 | 0.95 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL30255149 | 0.95 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL30254990 | 0.93 | SSTR2 (0.54) | SSTR2KCNH2SSTR5 | |
| SCHEMBL20500407 | 0.93 | SSTR2 (0.54) | SSTR2KCNH2SSTR5 | |
| SCHEMBL20500503 | 0.91 | SSTR2 (0.56) | SSTR2KCNH2SSTR5 | |
| SCHEMBL20500507 | 0.91 | SSTR2 (0.59) | SSTR2KCNH2 | |
| SCHEMBL20500329 | 0.89 | SSTR2 (0.59) | SSTR2KCNH2SSTR5 | |
| SCHEMBL30255104 | 0.89 | SSTR2 (0.59) | SSTR2KCNH2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110650951-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-11072598-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-27 | — | — | US | claimed |
| WO-2018170284-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-09-20 | — | — | WO | claimed |
| CN-110650951-B | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-11072598-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-27 | — | — | US | disclosed |
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2018170284-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072598-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SSTR2 2/4885KCNH2 4091/4885SSTR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.